Healthcare AI Governance: A Practical Framework for Clinical and Operational AI | AI Governance

This post is part of the Regulated AI Implementation pillar.

Healthcare AI sits at an unusual intersection. The potential for benefit is higher than almost any other domain — AI that improves diagnostic accuracy, reduces medication errors, or identifies deteriorating patients earlier can save lives. The accountability requirements are correspondingly high: decisions affect individual patients, errors may cause irreversible harm, and the evidence standard for clinical decisions is centuries old.

The challenge is that most AI governance frameworks were designed for financial services — where "defensible" means "I can show the regulator a decision record." In healthcare, "defensible" means "I can show a clinician, a patient, and potentially a jury that this system's output was appropriate, within its validated scope, and did not substitute for clinical judgment when clinical judgment was required."

This post applies the Architecture of Proof framework to two categories of healthcare AI: clinical decision support and operational healthcare AI.

Two categories, two governance profiles

Clinical AI — systems that affect patient diagnosis, treatment plans, medication recommendations, workflow prioritization, or clinical documentation.

Operational healthcare AI — systems that affect scheduling, resource allocation, billing coding, claims processing, supply chain, or administrative workflows.

The governance requirements differ substantially.

Clinical AI carries the highest individual-level accountability requirements: a patient who receives a harmful recommendation has a right to understand what the system contributed and whether it was applied within its validated scope. Regulatory frameworks in most jurisdictions classify some clinical AI as software as a medical device (SaMD), with corresponding pre-market requirements.

Operational healthcare AI carries governance requirements closer to financial services — defensible decisions, audit trails, fair treatment — but without the direct patient harm pathway that clinical AI introduces.

This post focuses primarily on clinical AI governance, with a section on operational AI at the end.

The default autonomy principle for clinical AI

The most important governance principle for clinical AI is the most frequently violated one:

Clinical AI must default to Tier 0 (Observe and Suggest) unless there is explicit clinical evidence and institutional sign-off to operate at a higher tier.

This means: the system presents its output to a clinician. The clinician independently considers the recommendation. The clinician makes the clinical decision. The system does not make the clinical decision.

This is not a conservative design choice. It is the standard of care for clinical decision support in most jurisdictions. AI that drives clinical action without clinician review is subject to the highest regulatory scrutiny, the most demanding validation requirements, and the most significant liability exposure.

The exceptions — where higher tiers are appropriate — are narrow and specific: - Administrative workflows with no direct patient impact (scheduling, routing, billing triage) - High-confidence, well-validated, narrow-scope alerts where the literature supports autonomous action (e.g., specific drug-drug interaction alerts in a validated pharmacy system)

The default is Tier 0. Every deviation from Tier 0 requires clinical evidence, institutional governance review, and regulatory compliance assessment.

Composite system design for clinical AI

Rules layer — what rules must encode:

Rules in clinical AI are not eligibility filters. They are clinical safety constraints that must never be violated regardless of model output.

Contraindication rules: If a patient has a documented allergy to a medication class, no AI system may recommend that medication, regardless of model confidence. This is not a high-threshold model output — it is a hard rule. The rule fires before the model is called. The model output cannot override it.

Population scope rules: The AI system must not produce recommendations for patient populations outside its validated scope. A model validated on adult inpatients must not be applied to pediatric patients or outpatients without separate validation.

Mandatory review rules: Certain recommendation categories must always route to a senior clinician, a specialist, or a multi-disciplinary team — regardless of model confidence. No AI output in these categories should reach a clinician as a standalone recommendation without this routing.

Model layer — what models provide:

Clinical AI models provide probabilistic estimates — risk scores, likelihood assessments, differential diagnosis rankings. They do not provide diagnoses. They do not provide treatment decisions. They provide inputs to clinical judgment.

The model contract must specify: - The patient population the model was validated on (age range, condition, care setting) - The clinical outcome the model predicts and the timeframe of the prediction - The performance metrics on which the model meets its validation standard, and on which patient subgroups - The inputs the model requires and what happens if those inputs are missing or outside expected ranges

Human layer — what clinicians do:

In clinical AI, the human layer is not a safety backstop. It is the primary decision-making entity. The AI provides support; the clinician makes the decision.

This means: - The clinician must be able to see the basis of the AI recommendation — not just the recommendation - The clinician must be able to dismiss, override, or escalate any recommendation - When the clinician acts contrary to an AI recommendation, the override must be logged with a reason

Override logging in clinical AI is not an administrative formality. It is the primary signal that a model is producing recommendations outside its validated distribution. High override rates in a specific patient segment indicate the model is not performing as designed in that segment.

Contraindication enforcement: why it must be rules, not models

This is the most common design error in clinical AI systems.

Some organizations implement contraindication checking as a model feature — the model learns, from training data, to avoid recommending contraindicated medications. This is insufficient.

A model that has learned to avoid contraindications will fail in the same way all models fail: on inputs outside its training distribution. A rare drug-drug interaction may not appear frequently enough in the training data for the model to learn it reliably. A patient with an unusual combination of conditions may present a contraindication pattern the model has never seen.

Contraindications must be encoded as deterministic rules. The rule fires before the model is called. The rule cannot be overridden by a model score. The rule fires for every patient in every setting where the system is deployed, regardless of model confidence.

This is not a technical constraint. It is a clinical safety requirement.

Clinical outcome linkage

Clinical AI systems must be connected to patient outcomes at the cohort level. Not for individual attribution — a clinician's decision about an individual patient involves judgment factors the AI cannot see — but for population-level safety monitoring.

What outcome linkage detects: - Whether patients who received AI-recommended treatments have systematically different outcomes than those who did not - Whether patient subgroups (by age, demographic, comorbidity profile) show disparate outcomes that suggest the model performs differently across groups - Whether the model's predictions correlate with actual outcomes at the rates its validation suggested

Minimum requirements: - Outcome data linked to AI recommendation episodes for all high-consequence recommendation categories - Quarterly cohort-level analysis comparing outcomes for AI-influenced vs. uninfluenced clinical decisions - Immediate review triggered by any finding of disparate outcomes across patient demographic groups

Operational healthcare AI governance

Operational healthcare AI — scheduling, resource allocation, billing coding, administrative routing — follows governance principles closer to financial services than to clinical AI.

The key distinction from clinical AI: operational AI decisions affect patients indirectly. They are governed by the same composite accountability principles — explicit contracts, local metrics, decision traces — but without the clinical safety constraints that make Tier 0 the default.

The regulatory landscape

Healthcare AI governance intersects with multiple regulatory frameworks depending on jurisdiction and use case.

United States: FDA SaMD guidance applies to clinical AI intended to diagnose, treat, or manage disease. ONC certification rules apply to health IT systems. State-level regulations on AI in clinical practice are evolving.

European Union: EU AI Act classifies AI in medical device contexts as high-risk, requiring conformity assessment, transparency obligations, and registration. The Medical Device Regulation (MDR) applies to clinical AI that qualifies as a medical device.

All jurisdictions: Clinical AI that influences individual patient care decisions is subject to professional liability standards — the AI system is not the clinician; the clinician who relies on it may bear responsibility for the recommendation.

Governance design cannot be decoupled from regulatory counsel. The Architecture of Proof framework provides the operational structure; regulatory compliance determines the applicable standards for each system.

Related reading

• Regulated AI Implementation: The full pillar covering all regulated implementation domains.
• Autonomy Tier Assignment: The decision framework for determining the right level of AI autonomy in clinical contexts.
• How to Write AI Component Contracts: Practical guide for writing the contracts that clinical AI models must meet.
• Fraud Detection AI Governance: Comparison case study from financial services showing different tier design considerations.